Skip to main content
Category

Research

Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity ResearchTreatments

Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity

*August 2019*  Science Immunology Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a first-line therapy for rapidly killing tumors such as those associated with non–small cell lung cancer by blocking oncogenic receptor signaling, but tumor relapse often occurs. Here, we have observed that hypofractionated EGFR TKI treatment (HypoTKI)…
laurabbook@gmail.com
September 25, 2019
cancerconnect
In Depth Overview of Tyrosine Kinase Inhibitor Treatment of EGFR+ Lung Cancer ResearchTreatments

In Depth Overview of Tyrosine Kinase Inhibitor Treatment of EGFR+ Lung Cancer

*July 2019* by Dr. C.H. Weaver M.D. for CancerConnect.  Tagrissio, Tarceva and other TKI therapy for EGFR + NSCLC continue to evolve and improve survival. Advances in cancer research have highlighted the importance of understanding the specific characteristics of each person’s cancer. These characteristics—which include not only the particular type of…
laurabbook@gmail.com
August 12, 2019
Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer Research

Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer

*July 2019* The Oncologist. With the advent of immunotherapy, substantial progress has been made in improving outcomes for patients with advanced cancer. However, not all patients benefit equally from treatment, and confounding immune‐related issues may have an impact. Several studies suggest that antibiotic use (which alters the gut microbiome) may…
laurabbook@gmail.com
August 12, 2019
EGFR Resisters logo
Video: Next Generation Sequencing for EGFR Mutant Lung Cancer: How it Guides Treatment Today & Tomorrow ResearchTreatments

Video: Next Generation Sequencing for EGFR Mutant Lung Cancer: How it Guides Treatment Today & Tomorrow

The EGFR Resisters hosted Dr. Josh Bauml for an extremely informative Facebook Live presentation on "Next Generation Sequencing for EGFR Mutant Lung Cancer: How it Guides Treatment Today & Tomorrow. https://www.youtube.com/watch?v=GRVMj_AbVOs&feature=youtu.be
laurabbook@gmail.com
July 6, 2019
1st Annual EGFR Resisters Research Summit – November 15-16, 2019 in Chicago Research

1st Annual EGFR Resisters Research Summit – November 15-16, 2019 in Chicago

We are very excited to announce that the EGFR Resisters will be holding our first Research Summit in collaboration with CEC Oncology, thanks to an independent educational grant from AstraZeneca. We are currently inviting Young Investigators (Junior Faculty or Fellows) in the EGFR lung cancer space to submit abstracts to…
laurabbook@gmail.com
July 6, 2019
Warning: Using Osimertinib After Immunotherapy ResearchTreatments

Warning: Using Osimertinib After Immunotherapy

*June 2019*  Medscape.  The latest research indicates immunotherapy followed by osimertinib resulted in serious irAEs (severe immune related adverse events) in some advanced lung cancer patients. Medscape (3/20, Castellino, Subscription Publication) reports a study team “notes that serious iirAEs were seen when osimertinib was given after immunotherapy in six of 41…
laurabbook@gmail.com
June 18, 2019